CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma

Blood

Volumn 121, Issue 23, 2013, Pages 4740-4748

  Rubenstein, James L ^a   Wong, Valerie S ^a   Kadoch, Cigall ^a   Gao, Hua Xin ^a   Barajas, Ramon ^b   Chen, Lingjing ^a   Josephson, S Andrew ^c   Scott, Brian ^c   Douglas, Vanja ^c   Maiti, Mekhala ^a   Kaplan, Lawrence D ^a   Treseler, Patrick A ^c   Cha, Soonmee ^b   Hwang, Jimmy H ^a   Cinque, Paola ^d   Cyster, Jason G ^c   Lowell, Clifford ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 10; JANUS KINASE 1; PREDNISONE; STROMAL CELL DERIVED FACTOR 1; TUMOR MARKER; VINCRISTINE; CXCL13 PROTEIN, HUMAN; MESSENGER RNA;

ADULT; ARTICLE; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL ISOLATION; CHEMOTAXIS ASSAY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MOLECULAR PATHOLOGY; MULTICENTER STUDY; NERVOUS SYSTEM INFLAMMATION; PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CHEMOTAXIS; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENETICS; LYMPHOMA; MORTALITY; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADULT; ANIMALS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOKINE CXCL13; CHEMOTAXIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-10; LYMPHOMA; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84881057567     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-476333     Document Type: Article

References (40)

1. Josephson SA, Papanastassiou AM, Berger MS, et al. The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg. 2007;106(1):72-75.
2. Hall WA. The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer. 1998; 82(9):1749-1755.
3. Javedan SP, Tamargo RJ. Diagnostic yield of brain biopsy in neurodegenerative disorders. Neurosurgery. 1997;41(4):823-828, discussion 828-830.
4. Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510-522.
5. Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126(2):202-208.
6. Abrey LE, Batchelor TT, Ferreri AJ, et al; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043.
7. Haldorsen IS, Espeland A, Larsen JL, Mella O. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005;44(7): 728-734.
8. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol. 1999;17(2): 554-560.
9. Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140-3146.
10. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005; 65(21):9628-9632.
11. Kim K, Chadalapaka G, Lee SO, et al. Identification of oncogenic microRNA-17-92/ ZBTB4/specificity protein axis in breast cancer. Oncogene. 2012;31(8):1034-1044.
12. Malzkorn B, Wolter M, Liesenberg F, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2010;20(3):539-550.
13. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26(1):96-105.
14. Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro-Oncol. 2012;14(3):368-380.
15. Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19): 5968-5973.
16. Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716-3723.
17. Kadoch C, Dinca EB, Voicu R, et al. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009;15(6):1989-1997.
18. Offit K, Parsa NZ, Gaidano G, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin’s lymphoma. Blood. 1993;82(7): 2157-2162.
19. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283-298.
20. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-577.
21. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
22. Cyster JG, Ngo VN, Ekland EH, Gunn MD, Sedgwick JD, Ansel KM. Chemokines and B-cell homing to follicles. Curr Top Microbiol Immunol. 1999;246:87-92, discussion 93.
23. Ansel KM, Harris RB, Cyster JG. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity. 2002;16(1):67-76.
24. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101(3):815-821.
25. Sellebjerg F, Börnsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73(23):2003-2010.
26. Panse J, Friedrichs K, Marx A, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 2008; 99(6):930-938.
27. Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4): 1146-1155.
28. Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM. Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol. 2007;127(4):633-641.
29. Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012;119(12):2844-2853.
30. Rubenstein JL, Li J, Chen L, et al. Multicenter phase I trial of intraventricular immuno-chemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745-751.
31. Sung CO, Kim SC, Karnan S, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood. 2011;117(4):1291-1300.
32. Wang V.S., Chen L., Kadoch C., et al. Multivariate analysis of cerebrospinal fluid biomarkers in central nervous system lymphoma and controls [abstract]. Cancer Res. 2010;70(8, suppl 1):2728. Abstract 2728.
33. Chan CC, Whitcup SM, Solomon D, Nussenblatt RB. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol. 1995;120(5):671-673.
34. Buggage RR, Whitcup SM, Nussenblatt RB, Chan CC. Using interleukin 10 to interleukin 6 ratio to distinguish primary intraocular lymphoma and uveitis. Invest Ophthalmol Vis Sci. 1999;40(10): 2462-2463.
35. Chunsong H, Yuling H, Li W, et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD231CD51 B cells. J Immunol. 2006; 177(10):6713-6722.
36. Sáez de Guinoa J, Barrio L, Mellado M, Carrasco YR. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood. 2011;118(6):1560-1569.
37. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 2003;9(1):316-326.
38. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res. 2001;7(3):709-723.
39. Whitcup SM, Stark-Vancs V, Wittes RE, et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol. 1997; 115(9):1157-1160.
40. van Burgel ND, Bakels F, Kroes AC, van Dam AP. Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. J Clin Microbiol. 2011;49(5): 2027-2030.